BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment
BiVictriX Therapeutics plc (AIM: BVX), a pioneering drug discovery and development company, has announced receiving a substantial grant of £0.37 million from Innovate UK. This ... Read More
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval ... Read More
Aravive Biologics’ AVB-S6-500 receives FDA fast track designation for ovarian cancer
Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel drug AVB-S6-500, aimed at ... Read More